Consensus recommendations from Wall Street equity research analysts covering Abeona Therapeutics lean predominantly toward a Buy rating. Analysts point to the company's proprietary gene therapy platform and advancement toward commercialization as core catalysts, though biotechnology investments remain sensitive to regulatory timelines and funding requirements.